ZW327, a novel Ly6E-targeting antibody-drug conjugate bearing a topoisomerase 1 inhibitor payload
ZW327, a novel Ly6E-targeting antibody-drug conjugate bearing a topoisomerase 1 inhibitor payload
ZW171, a differentiated 2+1 T cell-engaging bispecific antibody with antitumor activity in a range of mesothelin-expressing cancers
ZW171, a differentiated 2+1 T cell-engaging bispecific antibody with antitumor activity in a range of mesothelin-expressing cancers
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
The Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
TriTCE Co-Stim: A next generation trispecific T cell engager platform with integrated CD28 co-stimulation, engineered to improve responses in the treatment of solid tumors
TriTCE Co-Stim: A next generation trispecific T cell engager platform with integrated CD28 co-stimulation, engineered to improve responses in the treatment of solid tumors
DLL3 TriTCE Co-Stim: A next generation trispecific T cell engager with integrated CD28 co-stimulation for the treatment of DLL3-expressing cancers
DLL3 TriTCE Co-Stim: A next generation trispecific T cell engager with integrated CD28 co-stimulation for the treatment of DLL3-expressing cancers
Development of three-dimensional cancer cell line spheroid models for the in vitro functional characterization of cytotoxic antibody-drug conjugates
Development of three-dimensional cancer cell line spheroid models for the in vitro functional
characterization of cytotoxic antibody-drug conjugates
Screening novel format antibodies to design bispecific ADCs that address target heterogeneity
Screening novel format antibodies to design bispecific ADCs that address target heterogeneity
ZW191 – a FRα-targeting antibody-drug conjugate with strong preclinical activity across multiple FRα-expressing indications
ZW191 – a FRα-targeting antibody-drug conjugate with strong preclinical activity across multiple FRα-expressing indications
